Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

AlzeCure Pharma

1.96 SEK

Less than 1K followers

ALZCUR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Valuation

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for AlzeCure Pharma

EV/EBIT

Median 2019-2021

P/B

Median 2019-2025

 
2019202020212022202320242025
Share price (SEK)3.537.805.123.712.791.092.00
Shares43.943.943.956.669.392.9114.9
Market cap154.8342.2224.7210.0193.1101.5229.8
Enterprise value-27.7229.7183.0----
EV/S-------
EV/EBITDA0.5neg.neg.----
EV/EBIT0.5neg.neg.----
P/Eneg.neg.neg.neg.neg.neg.neg.
P/B0.853.096.813.478.123.886.98
P/S-------
Dividend yield0.0 %0.0 %0.0 %0.0 %0.0 %0.0 %0.0 %
Equity ratio97.5 %94.0 %72.2 %85.4 %74.3 %76.0 %55.8 %
Gearing ratio------7.8 %
Login required

This content is only available for logged in users

Create account
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.